Key result
Statin therapy increased HbA1c by 0.05% compared to a 0.04% decrease in non-users and worsened insulin resistance in elderly patients.
Why the study?
The study was designed to investigate the influence of statin therapy on glycemic control across different age groups.
Does statin therapy worsen glycemic control in patients with suspected or confirmed coronary artery disease across different age groups?
Cohort (n=2,654)
No
Does statin therapy worsen glycemic control in patients with suspected or confirmed coronary artery disease across different age groups?
Answers are grounded in this paper and cite their sources.
Statin therapy is associated with a slight worsening of glycemic control, particularly increasing insulin resistance in elderly patients with coronary artery disease.
The aim of this study was to investigate the influence of statin on glycemic control in different age groups. Patients admitted for suspected or confirmed coronary artery disease between January 2005 and December 2013 in Seoul, Korea were initially enrolled. After propensity score matching, 2654 patients (1:1 statin users and non-users) were selected out of total 5041 patients, including 1477 “young” patients (≤60 y) and 1177 elderly patients (>60 y). HbA1c was decreased by 0.04% (±0.86%) in statin non-users. On the contrary, a slight increment of 0.05% (±0.71%) was found in statin users (p < 0.001). The change patterns of HbA1c were constant in both young and elderly patient groups. Furthermore, elderly statin users demonstrated significantly worse glycemic control in serum insulin and homeostatic model assessment—insulin resistance (HOMA-IR) index. In elderly patients, statin users were found to have a 2.61 ± 8.34 μU/mL increment in serum insulin, whereas it was 2.35 ± 6.72 μU/mL for non-users (p = 0.012). Statin users had a 0.78 ± 3.28 increment in HOMA-IR, in contrast to the 0.67 ± 2.51 increment in statin non-users (p = 0.008). In conclusion, statin treatment was associated with adverse glycemic control in the elderly population.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) conducted a cohort in Suspected or confirmed coronary artery disease (n=2,654). Statin therapy vs. Statin non-users was evaluated on Change in HbA1c (%) (MD 0.09%, p=<0.001). Statin therapy increased HbA1c by 0.05% compared to a 0.04% decrease in non-users and worsened insulin resistance in elderly patients.
Synapse has enriched 10 related papers. Consider them for comparative context: